PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell - California Valley, California - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-03-29 05:35:06 Medicine Clinical medicine Cancer Melanoma RTT Uveal melanoma Cancer treatments Immunology Oncology Uvea Immunocore Cancer immunotherapy		PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell Add to Reading List Source URL: www.immunocore.com Download Document from Source Website File Size: 413,56 KB Share Document on Facebook

	PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell DocID: 1qYsI - View Document
	PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s ImmTAV shown to redirect the immune system to kill HIVinfected cells from patients treated with antiretroviral therapy - - DocID: 1q91g - View Document
	PRESS RELEASE – IMMUNOCORE LIMITED Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting - DocID: 1p2eO - View Document
	PRESS RELEASE – IMMUNOCORE LIMITED Immunocore named one of Fierce 15 leading biotechs of[removed]Oxford, UK, 24 September[removed]Immunocore Limited, the Oxford-based biotechnology company developing novel biological drug DocID: znUo - View Document
	ImmTAC Technology Overview Introducing the Technology The challenge for any immunotherapeutic strategy is to effectively target and eradicate diseased cells. Over recent years, antibodies in various guises have provided DocID: 74ke - View Document